Evidence map›Paper›PMID 30972078›Full record

ReviewFrontiers in immunology2019

Advances in mRNA Vaccines for Infectious Diseases.

Cuiling Zhang, Giulietta Maruggi, Hu Shan, Junwei Li

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 372 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
372citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

372 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

312 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cuiling ZhangCollege of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.
Giulietta MaruggiGSK, Rockville, MD, United States.
Hu ShanCollege of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.
Junwei LiCollege of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the last two decades, there has been broad interest in RNA-based technologies for the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have shown that mRNA vaccines provide a safe and long-lasting immune response in animal models and humans. In this review, we summarize current research progress on mRNA vaccines, which have the potential to be quick-manufactured and to become powerful tools against infectious disease and we highlight the bright future of their design and applications.

Indexed as

Communicable Disease ControlCommunicable DiseasesHumansRNA, MessengerVaccinationVaccines, SyntheticRNA, MessengerVaccines, Syntheticapplicationdeliveryinfectious diseasemechanismmRNA vaccine

Identifiers

PMID30972078
PMCPMC6446947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.